Three-Year Outcomes of Patients with Neovascular Age-Related Macular Degeneration Treated with Aflibercept under the National Health Insurance Program in Taiwan

Table 1

Univariate and multivariate analysis for visual outcome at the third year in the complete 3-year follow-up group (n = 99).

n = 99	Univariate analysis		Multivariate analysis
		value		value
Age	0.292	0.003	−0.046	0.469
Sex	0.133	0.189	0.104	0.085
Visual acuity
Baseline	0.62	<0.001
3^rd month	0.686	<0.001
1^st year	0.765	<0.001	0.717	<0.001
2^nd year	0.89	<0.001
Central macular thickness (CMT)
Baseline	0.094	0.395
3^rd month	−0.148	0.204
1^st year	−0.027	0.807	−0.04	0.626
2^nd year	−0.053	0.628
Others
SRF at baseline	−0.074	0.493
SRF at 1^st year	−0.044	0.691	−0.047	0.425
IRC at baseline	0.306	0.004
IRC at 1^st year	−0.028	0.802	−0.08	0.284
RPED at baseline	0.067	0.538
RPED at 1^st year	−0.02	0.855	0.166	0.011
Number of injections
1^st year	−0.219	0.029
>4 in 1^st year	−0.533	<0.001	−0.301	<0.001
Total	−0.293	0.003

Statistically significant. SRF, subretinal fluid; IRC, intraretinal cyst; RPED, retinal pigment epithelial detachment.